Vision-Sciences Inc (VSCI) Reports Q1 Loss of $0.04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Vision-Sciences Reports First Quarter Fiscal 2015 Results
August 4, 2014 4:30 PM EDTORANGEBURG, N.Y., Aug. 4, 2014 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc. (Nasdaq: VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath® technology, today announced financial results for the first quarter of fiscal 2015, ended June 30, 2014.
First Quarter Fiscal Year 2015 Highlights
Net sales increased 3% to $3.8 million as compared with $3.7 million in first quarter of fiscal 2014; Operating loss improved 21% to $(1.9) million; Net loss improved by 19% to $(2.0) million, or ($0.04) per basic and diluted share; and Vision-Sciences chose not to renew an agreement with Stryker Corporation for the... More